Several experimental studies have shown that PAI-1 inhibitors can inhibit metabolic dysregulation, improve endothelial function, and prevent atherosclerosis in the setting of diet-induced obesity [31,211,268,269]. Here, SERPINE1 is linked to obesity disorder.